Johnson & Johnson's TREMFYA (guselkumab) demonstrated significantly higher combined fistula remission rates in adults with perianal fistulizing Crohn's disease at Week 24 compared to placebo in the Phase 3 FUZION study. This marks the first randomized controlled trial in 20 years to show efficacy for this challenging Crohn's disease complication, offering hope for improved management of a debilitating condition. The study's positive results support TREMFYA as a new treatment option, with ongoing research including a head-to-head trial against another IL-23 inhibitor underway.
Amplify CWP Enhanced Dividend Income ETF (DIVO) has gained 6.6% year-to-date but lags the S&P 500 due to high 10-year Treasury yields near 4.62%, which limit dividend stock valuations. The ETF combines blue-chip dividend growers like Johnson & Johnso...
The iShares Core Dividend Growth ETF (DGRO) is facing challenges as the 10-year Treasury yield approaches its 12-month high. This makes DGRO's dividend growth less attractive compared to risk-free Treasury notes. Investors should monitor the 10-year ...
Vanguard High Dividend Yield ETF (VYM) manages $94.6 billion in assets, focusing on large-cap U.S. stocks with high dividend yields. Its top holdings, including Johnson & Johnson and Procter & Gamble, have strong dividend coverage and consistent payo...
The NEOS S&P 500 High Income ETF (SPYI) has returned 8% year-to-date and 19% over the past year, driven mainly by its 12% annualized distribution from selling call options on S&P 500 stocks. However, with market volatility (VIX) decreasing below its ...
Johnson & Johnson reported strong Q2 earnings, driven by a 41.1% year-on-year sales increase of its depression treatment Spravato, reaching $584 million. The company raised its 2026 adjusted diluted EPS guidance from $11.45-$11.65 to $11.6-$11.75, re...
